Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings

Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017

“…Studies on the economic burden or costs of prostate cancer were mainly focused on the United States, Europe countries (Sanyal et al, 2013;Smith-Palmer et al, 2019), or other developed countries (Grover et al, 1999;Grover et al, 2000;Krahn et al, 2010;Kitazawa et al, 2015;Mervin et al, 2017;Satoh et al, 2018). Only a few studies described the medical expenditure of Chinese patients with metastatic prostate cancer and presented a high prevalence of bone metastasis among Chinese prostate cancer patients (Qian et al, 2019;Zhuo et al, 2019). However, evidence on health care utilization and medical expenditure focused on prostate cancer has been absent in China.…”

Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study

“…13 A retrospective study analyzed clinical data of Chinese patients who had developed metastatic castrate-resistant prostate cancer (mCRPC) from 2012 to 2016 and reported that 75% of Chinese patients presented with a delayed diagnosis of CRPC and 91% with bone metastasis. 14 Limited treatment options for these patients was recognized as an important unmet clinical need. 14 In Asian countries, access to agents other than cytotoxic chemotherapy may vary across the region.…”

“…14 Limited treatment options for these patients was recognized as an important unmet clinical need. 14 In Asian countries, access to agents other than cytotoxic chemotherapy may vary across the region. 15 In China, radical prostatectomy or radical radiotherapy are the main treatment options for localized prostate cancer, and androgen deprivation therapy (ADT) is often used for the treatment of advanced disease, 16 whereas patients with mCRPC also often receive docetaxel following first-or second-line hormonal therapy.…”

“… 14 Limited treatment options for these patients was recognized as an important unmet clinical need. 14 …”

Caracterización y evolución clínica de los pacientes con cáncer de próstata metastásico resistente a la castración atendidos en el servicio de urología de SOLCA (Guayaquil). 2013 a 2019

“…En la cohorte retrospectiva del estudio de Qian [17], de un hospital de tercer nivel, con 78 pacientes, encontró que aquellos pacientes con mCRPC se caracterizaron por un diagnóstico tardío de cáncer de próstata y una alta prevalencia de metástasis ósea, el 66% de los pacientes identificados solo recibió un episodio de tratamiento. La quimioterapia se asoció con costos de medicamentos comparables y costos no farmacológicos más altos en comparación con la terapia hormonal después del ajuste de las características del paciente A nivel local Villanueva J., en el Hospital Abel Gilbert Pontón (Guayaquil) durante el año 2016 a 2017, en 140 pacientes con adenocarcinoma de próstata, el cáncer de próstata se presentó especialmente en hombres de estrato socioeconómico bajo, acompañados por factores como sobrepeso, hipertensión arterial, uropatía obstructiva y tabaquismo [18].…”